GLAXOSMITHKLINE PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of GLAXOSMITHKLINE PHARMACEUTICALS have decreased by -0.80% YoY .
The Earnings Per Share (EPS) of GLAXOSMITHKLINE PHARMACEUTICALS has decreased by -63.96 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
GLAXOSMITHKLINE PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 500660|NSE : GLAXO]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹3,252 Cr | ₹3,278 Cr | ₹2,926 Cr | ₹3,224 Cr | ₹3,128 Cr |
| Expenses | ₹2,447 Cr | ₹2,516 Cr | ₹2,327 Cr | ₹2,567 Cr | ₹2,527 Cr |
| Operating Profit (Excl OI) | ₹804 Cr | ₹762 Cr | ₹598 Cr | ₹657 Cr | ₹601 Cr |
| Other Income | ₹101 Cr | ₹76 Cr | ₹111 Cr | ₹79 Cr | ₹102 Cr |
| Interest | ₹1.81 Cr | ₹2.00 Cr | ₹3.53 Cr | ₹6.34 Cr | ₹0.55 Cr |
| Depreciation | ₹66 Cr | ₹68 Cr | ₹79 Cr | ₹83 Cr | ₹49 Cr |
| Profit Before Tax | ₹836 Cr | ₹779 Cr | ₹454 Cr | ₹306 Cr | ₹683 Cr |
| Profit After Tax | ₹608 Cr | ₹381 Cr | ₹287 Cr | ₹93 Cr | ₹445 Cr |
| Consolidated Net Profit | ₹611 Cr | ₹1,695 Cr | ₹358 Cr | ₹93 Cr | ₹445 Cr |
| Earnings Per Share (Rs) | ₹36.05 | ₹100.04 | ₹21.14 | ₹5.50 | ₹26.29 |
| PAT Margin (%) | 17.03 | 10.59 | 9.19 | 2.77 | 14.24 |
| ROE(%) | 27.58 | 18.39 | 17.42 | 4.71 | 21.22 |
| ROCE(%) | 38.06 | 37.72 | 27.74 | 15.76 | 32.54 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 32,003.0 Cr |
| Revenue (TTM) | : | ₹ 3,311.4 Cr |
| Net Profit(TTM) | : | ₹ 528.9 Cr |
| EPS (TTM) | : | ₹ 31.2 |
| P/E (TTM) | : | 60.5 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLAXOSMITHKLINE PHARMACEUTICALS | -1.5% | -11.3% | 51% |
| SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
| CIPLA | 2.5% | 0.4% | 71.7% |
| DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
| ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
| DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
| MANKIND PHARMA | NA | NA | NA |
| TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
| LUPIN | 2.8% | 0% | 147.8% |
GLAXOSMITHKLINE PHARMACEUTICALS Revenues
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | -0.80 % |
| 5 Yr CAGR | 0.97 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹3,252 Cr | -0.80 | |
| Mar2022 | ₹3,278 Cr | 12.05 | |
| Mar2021 | ₹2,926 Cr | -9.27 | |
| Mar2020 | ₹3,224 Cr | 3.08 | |
| Mar2019 | ₹3,128 Cr | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Operating Profit
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | 5.57 % |
| 5 Yr CAGR | 7.56 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹804 Cr | 5.57 | |
| Mar2022 | ₹762 Cr | 27.37 | |
| Mar2021 | ₹598 Cr | -8.99 | |
| Mar2020 | ₹657 Cr | 9.40 | |
| Mar2019 | ₹601 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 6.41 % |
| 5 Yr CAGR | 6.52 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 24.73% | 6.41 | |
| Mar2022 | 23.24% | 13.64 | |
| Mar2021 | 20.45% | 0.34 | |
| Mar2020 | 20.38% | 6.09 | |
| Mar2019 | 19.21% | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Profit After Tax
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | -63.97 % |
| 5 Yr CAGR | 8.21 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹611 Cr | -63.97 | |
| Mar2022 | ₹1,695 Cr | 373.19 | |
| Mar2021 | ₹358 Cr | 284.26 | |
| Mar2020 | ₹93 Cr | -79.07 | |
| Mar2019 | ₹445 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 60.81 % |
| 5 Yr CAGR | 4.57 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 17.03 % | 60.81 | |
| Mar2022 | 10.59 % | 15.23 | |
| Mar2021 | 9.19 % | 231.77 | |
| Mar2020 | 2.77 % | -80.55 | |
| Mar2019 | 14.24 % | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | -63.96 % |
| 5 Yr CAGR | 8.21 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹36 | -63.96 | |
| Mar2022 | ₹100 | 373.23 | |
| Mar2021 | ₹21 | 284.36 | |
| Mar2020 | ₹5.50 | -79.08 | |
| Mar2019 | ₹26 | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | 0.90 % |
| 5 Yr CAGR | 4.00 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 38.06% | 0.90 | |
| Mar2022 | 37.72% | 35.98 | |
| Mar2021 | 27.74% | 76.02 | |
| Mar2020 | 15.76% | -51.57 | |
| Mar2019 | 32.54% | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹1,889.2 |
| Current MarketCap | : | ₹ 32,003.0 Cr |
| Updated EOD on | : | Apr 18,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAXOSMITHKLINE PHARMACEUTICALS | -1.5% |
-11.3% |
51% |
| SENSEX | -2.9% |
-0.4% |
20% |
GLAXOSMITHKLINE PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE 400 MIDSMALLCAP | -1.2% | 8.6% | 57.2% |
| S&P BSE MIDSMALLCAP | -1.2% | 9.4% | 62.3% |
| S&P BSE QUALITY | -1.3% | 3.6% | 46% |
| S&P BSE 150 MIDCAP | -1.4% | 6.9% | 55.2% |
| S&P BSE MID CAP | -1.4% | 6.8% | 62.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MID SMALL400 | -1.2% | 9.2% | 59.9% |
| NIFTY MIDCAP150 | -1.5% | 7.4% | 56.2% |
| NIFTY MIDCAP150 QUALITY 50 | -1.6% | 4.4% | 30.7% |
| NIFTY500 MULTICAP 50:25:25 | -1.8% | 5.7% | 44.8% |
| NIFTY LARGE MIDCAP 250 | -2% | 4.4% | 42.2% |
You may also like the below Video Courses
FAQ about GLAXOSMITHKLINE PHARMACEUTICALS Financials
How the annual revenues of GLAXOSMITHKLINE PHARMACEUTICALS have changed ?
The Revenues of GLAXOSMITHKLINE PHARMACEUTICALS have decreased by -0.80% YoY .
How the Earnings per Share (EPS) of GLAXOSMITHKLINE PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of GLAXOSMITHKLINE PHARMACEUTICALS has decreased by -63.96 % YoY .
Check out Intrinsic Value of Peers of GLAXOSMITHKLINE PHARMACEUTICALS
Compare Stock Analytics of Peers of GLAXOSMITHKLINE PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
